Novaccess Global Inc XSNX

Healthcare Biotechnology

NovAccess Global Inc. is a biopharmaceutical company, which develops immunotherapies to treat brain tumor patients in the United States. The Company specializes in research related to utilizing a patient’s own immune system to attack the cancer. Its dendritic cell-based immunotherapy utilizes a combination of Toll-like receptor adjuvants for an enhanced antitumor response. The therapy is designed to utilize the patient’s tumor antigens and immune cells, dendritic cells, in combination with TLR adjuvants to initiate an efficient antitumor immune response. This process includes obtaining the patients' tumor cells after surgery, and precursors cells that are matured into dendritic cells from peripheral blood. Its TLR-AD1 platform technology is a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. TLR-AD1 technology has a scope of use and is embodied in various different product lines for different clinical situations.

OTCPK:XSNX - Post by User

Novaccess Global Inc

Bullboard Posts

Comment by forcaster13on Jan 16, 2006 6:15pm

107 Views

Post# 10190574

RE: RRSP

ok this is my brokers response. We are good to hold XSNX in our rrsp's. 1) RRSP eligibility... is determined by CCRA (or whatever RevCan are calling themselves today).. I am not sure what the requirements are, but an example of an ineleigible investment are some closed-end funds (think hedge funds) and some Flow-through issues... it is very hit and miss, and there is no "rule of thumb". 2) Personal eligibility... Even if a stock is RRSP eligible, you may have indicated that a certain investment is not suitable for you. For example, if you are a 85 year old pensioner, you may have indicated that you only want Bonds and GIC investmens (low risk), so even though XSUNX is RRSP eligible (*in General*) it is not suitable *for you*... (high risk) FC13

Bullboard Posts

BMO evolves InvestorLine with enhanced tools for options trading